CPH •
Healthcare •
Diagnostics & Research •
Quote as of 07/24/2026
Company Profile
IndustryDiagnostics & Research
SectorHealthcare
ExchangeCPH
Market Capitalization522.33 mln
Float459 mln
Earnings Date08/20/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-2.9
Likely reliable
Relative Strength
98
/ 100
Top performer
Debt / Equity
0.12
Very low leverage
ROE
-155
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
BioPorto A/S is a Danish diagnostics company that develops and sells medical tests designed to identify acute kidney injury earlier and more accurately, giving doctors more time to act. Its core products measure a protein called NGAL in patient samples and are used in hospitals across Europe, North America, and Asia. The company also supplies research tools, including antibody products and ready-to-use test kits, supporting the development of diagnostics for a range of conditions such as diabetes, heart disease, and immune disorders.
